Ribo Life Science's Exciting Listing on the Hong Kong Stock Exchange
Ribo Life Science Co., Ltd. (stock code: 06938.HK) has made a remarkable debut by successfully listing on the Main Board of the Hong Kong Stock Exchange. This milestone not only highlights the growing importance of companies in the small interfering RNA (siRNA) therapeutics sector but also enhances the visibility of biopharmaceutical enterprises within the capital markets.
Investor Enthusiasm and Offering Details
In their global offering, Ribo issued a staggering 31,610,400 shares at an impressive offer price of HKD 57.97 each. The endeavor raised gross proceeds of over 1.8 billion Hong Kong dollars, with the Hong Kong public offering being over 100 times oversubscribed and the international placing receiving a remarkable 16.7 times oversubscription. Such overwhelming interest demonstrates global investors' robust confidence in the siRNA landscape and Ribo's innovative approaches.
Solid Financial Backbone
The funds raised from the IPO will serve as a strong financial foundation to propel Ribo's core business objectives. Notably, the offering garnered the support of 12 cornerstone investors, including prominent institutions like Arc Avenue, Ivy Rock, and Taikang Life Insurance. This indicates a solid endorsement from leading entities regarding Ribo's long-term vision and strategic direction.
Leadership's Vision for the Future
Speaking about the successful listing, Dr. Zicai Liang, the Founder, Chairman, and Chief Executive Officer of Ribo, expressed gratitude towards global investors for their trust. He emphasized that the listing marks a significant step in Ribo's journey toward enhancing the development and commercialization of siRNA therapeutics. Dr. Liang aims to utilize international capital markets to foster advancements in global clinical trials while ensuring the delivery of groundbreaking therapies to patients worldwide.
Strategic Allocation of Proceeds
The capital raised via the offering will be allocated to four significant areas: advancing global multicenter clinical trials for key products, supporting the development pipeline, upgrading siRNA delivery technologies, and replenishing operational capital for routine corporate functions.
Research and Development Commitment
Ribo Life Science boasts a fully integrated research and development platform, securing independent intellectual property rights. The company’s cutting-edge liver-targeting RiboGalSTAR delivery technology has successfully propelled several products into Phase II clinical trials. Furthermore, Ribo has established research centers in various regions, including Suzhou and Beijing, and has developed a global research network aimed at supporting drug development from initial discovery stages to comprehensive clinical testing.
Professional Support and Sponsorship
The listing process was affectionately backed by China International Capital Corporation and Citigroup, who provided pivotal support to facilitate Ribo’s entrance into the capital markets successfully. Their expertise reinforced Ribo’s strategic initiatives during this crucial phase of advancement.
About Ribo Life Science
Suzhou Ribo Life Science Co., Ltd. is a pioneering global biopharmaceutical company focused on developing and commercializing siRNA therapeutics. Utilizing their innovative siRNA technology and comprehensive pipeline, Ribo aims to address major health challenges, including cardiovascular, metabolic, liver, and kidney diseases. The company is dedicated to providing revolutionary treatment options through relentless innovation and cutting-edge research.
Frequently Asked Questions
What is Ribo Life Science known for?
Ribo Life Science specializes in developing small interfering RNA (siRNA) therapeutics, targeting key disease areas.
When did Ribo Life Science get listed?
Ribo successfully listed on the Main Board of the Hong Kong Stock Exchange recently, marking an important milestone.
What were the financial results of the IPO?
Ribo raised over 1.8 billion Hong Kong dollars, with the offering being greatly oversubscribed by both public and international investors, showcasing high confidence in the sector.
How does Ribo plan to use the funds from the IPO?
Funds from the IPO will support clinical trials, pipeline development, technology upgrades, and operational capital replenishment.
Who are some of Ribo's cornerstone investors?
Notable cornerstone investors include Arc Avenue, Ivy Rock, Springs Capital, and Taikang Life Insurance, reflecting institutional confidence in Ribo's future.
